Medical device manufacturer Medtronic has begun enrolling patients for a clinical trial to evaluate the safety and performance of its Endeavor II drug-eluting stent. The trial will evaluate Endeavor’s safety and efficacy and will support product approvals in 21 countries throughout Europe, the Middle East, Asia-Pacific, and Canada. The primary endpoint of the study is to target vessel failure at nine months.
Patient follow-up is currently underway and on schedule in the Endeavor I clinical study, which enrolled 100 patients in Australia and New Zealand. Preliminary results of the Endeavor I clinical study will be released at the Transcatheter Cardiovascular Therapeutics conference this September, according to the Minneapolis-based firm.
By AuntMinnie.com staff writersJuly 17, 2003
Related Reading
Cedara and Medtronic ink pact, May 27, 2003
Medtronic starts carotid stent clinical trials, January 31, 2003
Medtronic inks deal with Medamicus, October 15, 2002
Siemens, Medtronic ink 3-D fluoroscopy deal, August 22, 2002
Patent verdict against Medtronic overturned, April 2, 2002
Copyright © 2003 AuntMinnie.com
